Oppenheimer Asset Management Inc. decreased its position in iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) by 44.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,162 shares of the company's stock after selling 4,113 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in iRhythm Technologies were worth $465,000 as of its most recent filing with the SEC.
Several other large investors have also made changes to their positions in the company. WoodTrust Financial Corp lifted its holdings in iRhythm Technologies by 28.4% in the 3rd quarter. WoodTrust Financial Corp now owns 11,307 shares of the company's stock worth $839,000 after purchasing an additional 2,500 shares during the last quarter. Assetmark Inc. lifted its holdings in iRhythm Technologies by 8.0% in the 3rd quarter. Assetmark Inc. now owns 12,645 shares of the company's stock worth $939,000 after purchasing an additional 937 shares during the last quarter. State of New Jersey Common Pension Fund D lifted its holdings in iRhythm Technologies by 32.5% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 28,414 shares of the company's stock worth $2,109,000 after purchasing an additional 6,975 shares during the last quarter. Aigen Investment Management LP acquired a new stake in iRhythm Technologies in the 3rd quarter worth approximately $243,000. Finally, B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in iRhythm Technologies in the 3rd quarter worth approximately $1,522,000.
iRhythm Technologies Price Performance
Shares of IRTC stock traded up $0.36 during trading hours on Friday, hitting $101.75. 452,411 shares of the company's stock were exchanged, compared to its average volume of 473,223. The company has a debt-to-equity ratio of 9.00, a current ratio of 6.27 and a quick ratio of 6.12. iRhythm Technologies, Inc. has a 52 week low of $55.92 and a 52 week high of $128.52. The stock has a market cap of $3.20 billion, a price-to-earnings ratio of -27.95 and a beta of 1.36. The stock's 50-day moving average is $105.66 and its 200-day moving average is $86.53.
iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.30. iRhythm Technologies had a negative return on equity of 118.83% and a negative net margin of 19.14%. The business had revenue of $164.33 million for the quarter, compared to analyst estimates of $158.30 million. As a group, research analysts forecast that iRhythm Technologies, Inc. will post -1.98 EPS for the current year.
Wall Street Analyst Weigh In
IRTC has been the subject of a number of research analyst reports. Truist Financial upped their price target on iRhythm Technologies from $111.00 to $145.00 and gave the stock a "buy" rating in a report on Friday, February 21st. StockNews.com upgraded iRhythm Technologies from a "sell" rating to a "hold" rating in a research report on Monday, February 24th. Wells Fargo & Company upped their price target on iRhythm Technologies from $86.00 to $104.00 and gave the company an "equal weight" rating in a research report on Friday, February 21st. The Goldman Sachs Group upped their price target on iRhythm Technologies from $91.00 to $124.00 and gave the company a "neutral" rating in a research report on Monday, February 24th. Finally, Needham & Company LLC upped their price target on iRhythm Technologies from $125.00 to $138.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, iRhythm Technologies has an average rating of "Moderate Buy" and a consensus price target of $119.73.
Read Our Latest Analysis on IRTC
About iRhythm Technologies
(
Free Report)
iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Featured Articles
Before you consider iRhythm Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRhythm Technologies wasn't on the list.
While iRhythm Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
